Nick Paul Taylor
Nick Paul Taylor follows the money and risk in drug development, turning biotech news into clear stories about how clinical events and corporate decisions affect the business of pharmaceuticals. At Fierce Biotech he covers the biopharma business, with a focus on late-stage data, competitive dynamics and how investors and executives respond when experimental drugs succeed or fall short.
Biotech business framed through clinical outcomes
Taylor’s coverage starts from the science but is driven by what it means for the company’s strategy.
He writes about phase 2 and phase 3 readouts in terms of their impact on pipelines, partnerships and commercial prospects rather than only the underlying biology. In his reporting on Regeneron’s melanoma program failing to beat Keytruda in a phase 3 trial, he moves quickly from the headline result to what it means for Regeneron’s position in immuno-oncology and its effort to challenge an entrenched standard of care.
He routinely explains trial design, endpoints and patient populations just far enough for an industry audience to follow the stakes.
Technical terms such as phase design, primary endpoint and standard-of-care comparator sit alongside plain language about winners, losers and missed opportunities. That approach lets him show how a single dataset can change the commercial trajectory of a program, a franchise or a therapeutic area.
Setbacks are a recurring lens. Rather than treating a negative or inconclusive result as a dead end, he unpacks the implications for future indications, follow-on assets and rival companies in the same space.
The emphasis is on portfolio impact, reprioritisation and the questions boards and investors will be asking after the news lands.
Analyst insight and competitive context
Taylor frequently uses analyst reaction as a spine for his stories, reflecting the market-facing nature of his beat. In the Regeneron melanoma piece, the “shaking heads” response from analysts is not a throwaway quote but a signal of how the investment community is recalibrating its view of the asset and its chances against Keytruda. He elevates those reactions to the headline level when they capture the shift in sentiment or crystallise technical doubts in plain language.
Competitive context is central to how he frames drug news. A trial result is rarely presented in isolation; it is read against benchmark products, near-term rivals and combination strategies that matter to oncologists and payers. Keytruda’s established role in melanoma, for example, becomes the yardstick by which Regeneron’s effort is judged, and Taylor makes clear what failing to surpass that benchmark means for future uptake and differentiation.
Across his biopharma business coverage he tends to foreground questions such as: Will this result justify further investment?
How does it change the negotiation power in current or future partnerships? What does it signal for similar mechanisms under development elsewhere? Analyst notes, price moves and management commentary are used to answer those questions in concrete terms.
Concise, trade-focused style for industry readers
Taylor writes in the tight, news-driven style of a specialist trade outlet, assuming readers understand the basics of drug development and are looking for what is new, material and actionable. His pieces are compact, often moving from the topline result to business implications in the opening paragraphs, with methodological detail and secondary data points following in an ordered way.
Quotes are chosen for clarity rather than color.
Analyst lines, executive remarks and regulatory details are used to clarify risk, timelines and commercial prospects rather than to add personality. He avoids hype, instead adopting a measured tone that mirrors how cautious investors and development teams talk about probability of success.
Audience focus is evident in the way he balances clinical nuance with business takeaways. Trial acronyms, line-of-therapy distinctions and mechanism-of-action details are included when they change the size of the opportunity, the level of competition or the likelihood of regulatory success. When they do not, they stay in the background, keeping the narrative centered on capital allocation, strategic options and market impact.
Emphasis on reversals, risk and downside
A defining feature of Taylor’s work is his attention to the downside of biopharma, not only the upside.
Negative trials, unexpected safety signals and programs that fail to live up to expectations are treated as stories that matter just as much as breakthrough readouts. His Regeneron melanoma coverage leans into disappointment and confusion among analysts and stakeholders, reflecting how reversals reshape pipelines and investor theses.
He often highlights how companies respond to bad news: whether they double down on a mechanism, pivot to narrower indications or de-emphasise an asset altogether. By tracking these responses, he shows how management teams manage risk, communicate with markets and adjust their portfolios when data undercuts prior narratives.
That focus on reversals and risk gives his biopharma business reporting a pragmatic edge. For readers who follow biotech as operators, partners or investors, his stories map the gap between expectations and reality and explain how that gap feeds directly into valuations, deal terms and the future direction of drug pipelines.
4 more business journalists.
Aaron Karp
Aaron Karp is distinct for connecting airline networks, airport infrastructure, air cargo and policy. He is a senior editor at Air Transport World and has covered aviation since 1999. He has also worked as an editor for cargo-focused and daily aviation publications. His real beat is how airlines and airports respond to growth, regulation, trade conditions, sustainability pressures and technology changes. He covers route planning, network development, airport capacity, infrastructure, cargo flows, trade lanes, safety, air traffic control and future technology. He reports through news, features, opinion pieces, briefings and podcasts. He uses data, executive insight and industry conference reporting to explain market changes. His work links cargo metrics and trade policy to carrier strategy, and connects infrastructure and sustainability decisions to resilience, costs and long-term growth.
Adrienne Roberts
Adrienne Roberts is a business journalist at the Detroit Free Press who covers how policy, regulation and corporate decisions affect Michigan’s cannabis market, jobs, universities and health systems. She has a sustained focus on cannabis taxes, licensing, sales, product rules, consumer safety and local tax revenue. She also reports on unemployment, worker protections, corporate settlements, hiring, higher education, student safety, housing, data centers, health care access and economic forecasts. Roberts joined the Detroit Free Press in 2020 after covering automotive retail, dealers and labor issues for The Wall Street Journal. She explains complex business and regulatory changes with data, legal detail and on-the-ground voices. Her stories focus on practical effects for workers, students, consumers and communities, showing both the numbers and the people behind them.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex DeMarban
Alex DeMarban stands out for tracking major energy projects over time while showing how economic shifts affect local businesses. He reports for the Anchorage Daily News on business, oil and gas, and general assignments. His coverage focuses on Alaska LNG, long-haul energy projects, mining, ports, transportation infrastructure, and the everyday businesses that keep the state running. He examines financing, tax legislation, labor agreements, regulatory approvals, timelines and costs, and connects government and corporate decisions to workers, communities and consumers. He also reports on restaurant closures, grocery stores, breweries, meaderies, parking and trade disputes. His past coverage includes an open-pit mine near the proposed Ambler road, federal port grants and competitive elections. He reports through dollar figures, project details, public records, business owners and affected workers, showing how policy and resource development play out on the ground.